A novel perspective on pharmaceutical R&D costs: opportunities for reductions.

van der Schans, Simon; De Loos, Frans; Boersma, Cornelis; Postma, Maarten J; Büller, Hans

van der Schans, Simon; De Loos, Frans; Boersma, Cornelis; Postma, Maarten J; Büller, Hans.

Afiliação

van der Schans S; Unit of Global Health, Department of Health Science, University Medical Centre Groningen, Groningen, the Netherlands.
De Loos F; Fair Medicine Foundation, Amsterdam, the Netherlands.
Boersma C; Fair Medicine Foundation, Amsterdam, the Netherlands.
Postma MJ; Unit of Global Health, Department of Health Science, University Medical Centre Groningen, Groningen, the Netherlands.
Büller H; Faculty of Management Sciences, Open University, Heerlen, the Netherlands.

Expert Rev Pharmacoecon Outcomes Res ; 22(2): 167-175, 2022 Mar.

Article em En | MEDLINE | ID: mdl-34595997

Assuntos

Desenvolvimento de Medicamentos; Indústria Farmacêutica; Custos e Análise de Custo; Custos de Medicamentos; Humanos; Preparações Farmacêuticas

Palavras-chave

Affordability; R&D costs; cost of capital; cost of failure; cost-based pricing; drug development; transparency; value-based pricing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Indústria Farmacêutica / Desenvolvimento de Medicamentos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google